CureVac and GSK have intensified their collaboration by adding more resources and experts to accelerate the development and manufacturing of the extensive second-generation program. The companies plan to enter clinical development in the coming months in order to obtain regulatory approval for the marketing of an improved COVID-19 vaccine in 2022. Published preclinical results demonstrated the high potential of the first second-generation mRNA COVID-19 vaccine candidate, CV2CoV, compared to CureVac`s first-generation mRNA, cVnCoV. The data show up to 10 times higher immunogenicity in animal models. Alongside work on second-generation mRNA vaccine technology, GSK and CureVac will accelerate their efforts to advance the development of modified mRNA vaccines. Table 1 provides an overview of the composition of the partnership and the style of cooperation. Half of all partnerships with academics (51%) were “knowledge sharing” partnerships, compared to 43% of partnerships from industry only and only 26% of partnerships involving a government institution. There was no clear correlation between the use of conventional and next-generation vaccine platforms and the nature of cooperation (“knowledge sharing” versus “material transfer”) (Table 2). Partnerships used next-generation platforms slightly more often than going it alone (Table 2). Seungtaek Kim, Institut Pasteur Korea, Republic of Korea Not surprisingly, respondents noted restrictions on virtual communication and lockdown restrictions on collaboration. They also insisted on more clarity on data ownership and intellectual property (IP) – areas where discussions with academic peers have been difficult.
The simplest tools to improve this knowledge sharing are incentives such as public recognition or simply money. In this context, government contracts, especially pre-orders, have been crucial in reducing the risk of initial investment in vaccine development and capacity building. These contracts should contain strong requirements for knowledge exchange, now and in the future . Ideally, incentives or requirements for knowledge sharing would go beyond the entities involved, but as an intermediate step, the demand for knowledge sharing between stakeholders would at least begin to create externalities on knowledge. The most drastic measures could include knowledge-sharing mandates related to product regulatory approval . Of course, the requirements should not be too draconian, at the risk of reducing too much the incentives for upstream innovation . This webinar series provides factual information from experts working to protect public health during the COVID-19 pandemic. To increase the chances of success (given the large fluctuation during vaccine development), we need to test all vaccine candidates until they fail. Who is committed to ensuring that they all have the chance to be tested in the early stages of development. Use this AMA tool to determine the appropriate combination of CPT codes for the type and dose of vaccine used. Given the positive social externalities that can result from knowledge exchange, such as.B. better basic understanding, increased cumulative innovation and the ability to demonstrably avoid unproductive development pathways , policymakers should consider interventions to encourage partnerships that involve wider knowledge sharing and not just material transfer for serial innovation.
Knowledge exchange is particularly important for other technologies such as production methods. In addition to the contentious issues concerning the appropriate scope of monopolies for underlying products such as vaccines or therapeutic products, such monopolies, regardless of their size, should be subject to the express conditions of patents or exclusivity administered by regulators – and not to the disguised reality that no one else has the knowledge to manufacture a product, which is otherwise available for competition , . The exchange of relevant knowledge, including basic knowledge, relevant product-specific information or ancillary technologies, could reduce vaccine development times and enable sufficient global production of vaccines for the benefit of public health , , . We are scientists, physicians, funders and manufacturers who have come together in an international collaboration coordinated by the World Health Organization (WHO) to accelerate the availability of a COVID-19 vaccine. While it takes some time to develop a vaccine for general use, a vaccine can ultimately help control this global pandemic. In the meantime, we welcome the implementation of community response measures that reduce the spread of the virus and protect people, including vulnerable populations, and commit to using the time saved by the widespread adoption of such measures to develop a vaccine as quickly as possible. We will continue our efforts to strengthen the unprecedented global cooperation, cooperation and data exchange that is already underway. We believe these efforts will help reduce inefficiencies and duplication of effort, and we will work tirelessly to increase the likelihood that one or more safe and effective vaccines will soon be available to all. Once a safe and effective vaccine is available, it will be crucial that it is accessible to anyone who needs it. WHO will continue to work to harmonize research and development, accelerate regulatory approvals and manufacturing so that all people in all countries have access to a vaccine as soon as possible. WHO facilitates interaction between scientists, developers and donors to support coordination and/or provide common platforms for collaboration. .